Key result
High plasma indoxyl sulfate levels (≥ 0.79 µg/mL) predicted a significantly higher risk of cardiovascular events in patients with chronic heart failure (HR 1.84).
Why the study?
It was unclear whether plasma indoxyl sulfate levels predict cardiovascular events in patients with CHF, and which CHF etiologies leading to events are most influenced.
Do high plasma indoxyl sulfate levels predict cardiovascular events in patients with mild chronic heart failure?
Cohort (n=165)
No
Do high plasma indoxyl sulfate levels predict cardiovascular events in patients with mild chronic heart failure?
Hazard Ratio: 1.84 (95% CI 1.282–2.513)
Absolute Event Rate: 27.4% vs 12.3%
p-value: p=0.002
Elevated plasma indoxyl sulfate levels independently predict cardiovascular events in patients with mild chronic heart failure, particularly those with hypertrophic cardiomyopathy.
Elevated IS may flag higher CV event risk in CHF; leaves open whether measurement or targeting alters outcomes.
Indoxyl sulfate (IS) is associated with either chronic kidney disease or renal failure, which may predict cardiovascular events via cardiorenal syndrome. The present study aimed to elucidate whether the plasma levels of IS can predict the occurrence of cardiovascular events in patients with chronic heart failure (CHF) and investigate which causes of CHF leading to cardiovascular events are highly influenced by plasma IS levels. We measured the plasma IS levels in 165 patients with CHF [valvular disease: 78, dilated cardiomyopathy: 29, hypertrophic cardiomyopathy (HCM): 25 and others: 33] admitted to our hospital in 2012, and we followed up these patients for more than 5 years (the median follow-up period: 5.3 years). We measured the plasma IS level in 165 patients with CHF, and Kaplan-Meier analyses showed that high plasma IS levels (≥ 0.79 µg/mL, the median value) could predict the occurrence of cardiovascular events, i.e., cardiovascular death or rehospitalization due to the worsening of CHF. The sub-analyses showed that the high IS level could predict cardiovascular events in patients with CHF due to HCM and that the plasma IS levels were closely associated with left ventricular (LV) dimension, LV systolic dysfunction, and plasma B-type natriuretic peptide levels, rather than LV diastolic dysfunction. Plasma IS level predicts cardiovascular events in patients with CHF, especially those with HCM along with cardiac dysfunction. Besides, IS may become a proper biomarker to predict cardiovascular events in patients with CHF.
No takes yet. Share an insight, caveat, or question.
Imazu et al. (2020) conducted a cohort in Chronic heart failure (n=165). High plasma indoxyl sulfate levels (≥ 0.79 µg/mL) vs. Low plasma indoxyl sulfate levels (< 0.79 µg/mL) was evaluated on Cardiovascular events (cardiovascular death or rehospitalization due to worsening of heart failure) (HR 1.84, 95% CI 1.282-2.513, p=0.002). High plasma indoxyl sulfate levels (≥ 0.79 µg/mL) predicted a significantly higher risk of cardiovascular events in patients with chronic heart failure (HR 1.84).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: